The Development of New Nanoplatforms Based on Albumin and Graphene Oxide for Aticancer Therapy

Abstract

This study focuses on the covalent functionalization of the carboxylated graphene oxide layers with human serum albumin for developing new nanoplatforms capable of efficient drug loading and release for antitumor therapy. Thus, new GO-HSA conjugates have been developed and their interactions with methotrexate (MTX) molecules were evidenced through FT-IR, UV-Vis and Raman spectroscopy. The cumulative in vitro release profiles of MTX drug from GO-HSA-MTX nanoplatforms were analyzed through UV-Vis spectroscopy showing a more controlled release behavior of MTX drug under acidic conditions that simulate the tumor microenvironment demonstrating the potential use of GO-HSA-MTX as antitumoral nanocarriers.